MedMira (MedMira) Net Margin % : -396.40% (As of Jan. 2024)

View and export this data going back to . Start your Free Trial

What is MedMira Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. MedMira's Net Income for the three months ended in Jan. 2024 was $-0.44 Mil. MedMira's Revenue for the three months ended in Jan. 2024 was $0.11 Mil. Therefore, MedMira's net margin for the quarter that ended in Jan. 2024 was -396.40%.

The historical rank and industry rank for MedMira's Net Margin % or its related term are showing as below:

MMIRF' s Net Margin % Range Over the Past 10 Years
Min: -716.67 Med: -225.53 Max: -31.53
Current: -716.67

MMIRF's Net Margin % is ranked worse than
69.26% of 1028 companies
in the Biotechnology industry
Industry Median: -154.37 vs MMIRF: -716.67

MedMira Net Margin % Historical Data

The historical data trend for MedMira's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedMira Net Margin % Chart

MedMira Annual Data

Trend

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Net Margin %

Get a 7-Day Free Trial

-399.75

-222.47

-31.56

-192.39

-617.68

MedMira Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Net Margin %	Get a 7-Day Free Trial															-288.19	-554.43	-2,803.85	-661.63	-396.40

Competitive Comparison of MedMira's Net Margin %

For the Biotechnology subindustry, MedMira's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MedMira's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MedMira's Net Margin % distribution charts can be found below:

* The bar in red indicates where MedMira's Net Margin % falls into.

MedMira Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

MedMira's Net Margin for the fiscal year that ended in Jul. 2023 is calculated as

Net Margin	=	Net Income (A: Jul. 2023 )	/	Revenue (A: Jul. 2023 )
	=	-2.026	/	0.328
	=	-617.68 %

MedMira's Net Margin for the quarter that ended in Jan. 2024 is calculated as

Net Margin	=	Net Income (Q: Jan. 2024 )	/	Revenue (Q: Jan. 2024 )
	=	-0.44	/	0.111
	=	-396.40 %

MedMira (OTCPK:MMIRF) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

MedMira Net Margin % Related Terms

Thank you for viewing the detailed overview of MedMira's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

MedMira (MedMira) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedMira Inc (OTCPK:MMIRF) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

47M:Germany MIR:Canada

Address

155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3

Website

https://www.medmira.com

MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.